Online Inquiry

Global Services. (Creative Biolabs Authorized)

Flow Cytometry based Cell Surface CAR Expression Quantification (FACS PK) Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides Flow Cytometry-Based Cell Surface CAR Expression Quantification (FACS PK) Services to support precise pharmacokinetic characterization of CAR-engineered cell therapies. This service addresses challenges in tracking in vivo cell expansion and distinguishing functional surface CAR expression from total transgene copy numbers. Through advanced multiparameter flow cytometry and highly specific target-antigen or anti-idiotypic antibody probes, Creative Biolabs enables cell analysis of CAR expression dynamics, cellular persistence, and functional receptor profiles to support preclinical evaluation and translational development.

Introduction

The quantitative evaluation of CAR molecules on engineered immune cells is central to safety and efficacy profiles. Relying solely on qPCR or ddPCR can lead to an overestimation of functional therapy, as DNA transgene copy numbers do not always translate into properly folded cell-surface proteins. The multiparameter flow cytometry correlates closely with molecular assays while offering crucial phenotypic context. Quantitative flow cytometry remains the clinical standard to assess surface CAR density, positive cell percentages, and in vivo cellular kinetics.

Service

Evaluating chimeric antigen receptor (CAR) therapeutics requires moving beyond simple genomic presence to understanding actual surface protein expression. Creative Biolabs provides dedicated FACS PK analytical solutions to ensure your cellular therapeutic candidates are thoroughly characterized throughout their development life cycle.

In Vivo Persistence and PK Monitoring: We track the exact expansion and contraction kinetics of therapeutic cells within post-infusion patient or animal samples, delivering critical parameters based on functional protein expression.
Detailed Cellular Phenotyping: Our assays do not just count CAR-positive cells; they characterize them. We provide deep phenotypic profiles, distinguishing memory, effector, and exhausted states within the CAR-expressing subset.
Strict Quality Control and Release Testing: We support your manufacturing process by accurately establishing transduction efficiency, cell viability, and CAR expression stability on your final cell products before clinical release.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Analysis of Flow Cytometry-Based Cell Surface CAR Expression Quantification (FACS PK) Service. (Creative Biolabs Original)

Creative Biolabs uses robust non-infringing molecular detection platforms for diverse preclinical and clinical CAR designs: antigen-based detection, anti-idiotypic antibody assays, and universal linker/tag detection for accurate CAR expression measurement across different development stages.

Our Workflow

Required Starting Materials

Cryopreserved or fresh whole blood, or isolated Peripheral Blood Mononuclear Cells (PBMCs) from preclinical animal models or clinical trial subjects (minimum cell count and viability specifications will be coordinated before shipment).
Detailed CAR sequence information or structural details to select or design the optimal detection probe.

Workflow of Flow Cytometry-Based Cell Surface CAR Expression Quantification (FACS PK) Service. (Creative Biolabs Original)

Core Benefits

Highly Customized Assay Customization: Tailored panel development custom-fit to your specific cell therapy constructs, whether targeting CAR-T, CAR-NK, or CAR-Macrophage (CAR-M) systems.
Superior Specificity & Low Background: Custom generation of high-affinity anti-idiotypic antibodies or target-antigen probes to eliminate non-specific binding in complex clinical matrices.
Outstanding Sensitivity Thresholds: Validated detection protocols capable of tracking ultra-low CAR-positive cell frequencies down to 0.05% in patient whole blood or tissue-derived PBMCs.

FAQs

Q: What is the lower limit of detection (LOD) for tracking CAR-positive cells in clinical whole blood?

A: Our optimized FACS PK protocols can reliably detect and quantify target cells down to approximately 0.05% of the circulating T-cell population. This sensitivity allows for robust long-term persistence tracking even as the cell therapy contracts in vivo.

Q: Why should I choose FACS PK over ddPCR for pharmacokinetic monitoring?

A: While ddPCR is highly sensitive for detecting genomic DNA copies, it cannot distinguish between dead cells, non-expressing transgenes, and active, functional therapeutic cells. FACS PK measures active cell-surface CAR proteins on live cells, while simultaneously providing phenotype information.

Q: How do you address background non-specific staining in clinical samples?

A: We utilize rigorous gating controls, live/dead exclusion dyes, Fc-receptor blocking reagents, and biological negative controls. This ensures that any fluorescent signal captured is truly representative of specific CAR binding.

Partner with Us

Creative Biolabs offers a highly sensitive, robust, and regulatory-compliant Flow Cytometry-Based Cell Surface CAR Expression Quantification (FACS PK) Service. By combining state-of-the-art multi-laser flow cytometers with specific target-antigen and anti-idiotypic probes, we deliver precise quantification of cell-surface CAR expression, absolute subpopulation counts, and phenotypic maturation states in both preclinical and clinical matrices. Our services cover in-process quality control, release testing assays, and clinical-grade pk/pd persistence profiling, with experienced immunology specialists ready to support your program. Get in touch with our team for further details and to discuss your project.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.